|Bid||90.70 x 800|
|Ask||90.99 x 2200|
|Day's Range||90.42 - 91.34|
|52 Week Range||76.41 - 91.50|
|PE Ratio (TTM)||39.91|
|Earnings Date||Aug 21, 2018|
|Forward Dividend & Yield||2.00 (2.26%)|
|1y Target Est||95.55|
The ruling relates to a complex and years-long battle over how Medtronic accounted for business at its Puerto Rico manufacturing facilities.
Security researchers say they've found flaws in the Medtronic pacemaker that leaves the life-saving device vulnerable to hackers and puts patients at risk. The two researchers demonstrated the security weaknesses earlier this month at the annual Black Hat cyber security conference in Las Vegas. Security researchers say they've found flaws in the Medtronic MDT pacemaker that leaves the life-saving device vulnerable to hackers and puts patients at risk.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. Medtronic’s insiders have divested from 20.41k shares in the large-cap stock within theRead More...
Therapy Delivered via the Medtronic SynchroMed TM II Infusion System DUBLIN - August 16, 2018 - Medtronic plc (NYSE:MDT) today announced the online publication of `Effect of intrathecal baclofen on pain ...
August 15, 2018 - Medtronic plc (MDT) today announced full commercial launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) in Japan. IN.PACT Admiral received approval last year from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg - specifically, in the thigh (superficial femoral arteries (SFA)) and behind the knee (popliteal arteries). "In Japan, there is a significant need for new technologies to safely and effectively treat PAD," said Tony Semedo, president, Medtronic Japan.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.
Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It now expects adjusted EPS of $2–$2.15 compared to the previous estimate of $2.55–$2.65. The decrease represents Dentsply’s expectation of a decline in revenue for the remainder of 2018, driven by higher levels of inventory destocking at its dealer partners.
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%. In this series, we’ll explore its financial performance, how its segments are performing, its recent acquisitions, its valuation metrics, and what analysts expect in the coming months. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies.
After more than six months since its last high, the S&P 500 is back on the road to records. "We think the S&P is going to breakthrough that January resistance. You want to own stocks," Ari Wald, head of technical analysis at Oppenheimer, told CNBC's " Trading Nation " on Tuesday.
When her daughter, Sydney, was diagnosed with Type 1 diabetes at age 8, Kate Farnsworth stopped sleeping through the night. At 6 a.m., another alarm went off to signal the next insulin dose, but by then, Kate had usually snapped awake again already. When Sydney got home from school each afternoon, Kate was there to check her glucose level.
Mazor Robotics (NASDAQ:MZOR) fell nearly 15 percent last week after the company reported second-quarter results. Mazor Robotics reported revenue of $13.2 million as customers adopted its technologies in robotic guidance systems. At 20 times sales, MZOR stock is not cheap.
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.
Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.
IntriCon Corporation (NASDAQ:IIN) is a small company with big promise. Granted, its market cap is less than $500 million, so now that investors see the growth potential, the stock is getting a lot of attention from mutual funds, institutional investors and momentum traders.
System placements grew 25%, but lower pricing terms from its commercial deal with Medtronic cause the top line to head in reverse.
On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
Security researchers have discovered multiple security flaws that could allow a malicious hacker to tamper with a Medtronic pacemaker.